SEARCH

SEARCH BY CITATION

References

  • 1
    Bishop JE, Laurent GJ. Collagen turnover and its regulation in the normal and hypertrophying heart. Eur Heart J. 1995;16(suppl C):3844.
  • 2
    Lindsey ML, Mann DL, Entman ML, Spinale FG. Extracellular matrix remodeling following myocardial injury. Ann Med. 2003;35:316326.
  • 3
    Frangogiannis NG. Matricellular proteins in cardiac adaptation and disease. Physiol Rev. 2012;92:635688.
  • 4
    Villarreal FJ, Griffin M, Omens J, et al. Early short-term treatment with doxycycline modulates postinfarction left ventricular remodeling. Circulation. 2003;108:14871492.
  • 5
    Mann DL. The emerging role of innate immunity in the heart and vascular system: for whom the cell tolls. Circ Res. 2011;108:11331145.
  • 6
    Andrassy M, Volz HC, Igwe JC, et al. High-mobility group box-1 in ischemia-reperfusion injury of the heart. Circulation. 2008;117:32163226.
  • 7
    Vanhoutte D, Schellings M, Pinto Y, Heymans S. Relevance of matrix metalloproteinases and their inhibitors after myocardial infarction: a temporal and spatial window. Cardiovasc Res. 2006;69:604613.
  • 8
    Bornstein P. Matricellular proteins: an overview. J Cell Commun Signal. 2009;3:163165.
  • 9
    van Nieuwenhoven FA, Turner NA. The role of cardiac fibroblasts in the transition from inflammation to fibrosis following myocardial infarction. Vascul Pharmacol. 2012; [Epub ahead of print].
  • 10
    Dobaczewski M, de Haan JJ, Frangogiannis NG. The extracellular matrix modulates fibroblast phenotype and function in the infarcted myocardium. J Cardiovasc Transl Res. 2012;5:837847.
  • 11
    Ma Y, Halade GV, Lindsey ML. Extracellular matrix and fibroblast communication following myocardial infarction. J Cardiovasc Transl Res. 2012;5:848857.
  • 12
    Gharacholou SM, Alexander KP, Chen AY, et al. Implications and reasons for the lack of use of reperfusion therapy in patients with ST-segment elevation myocardial infarction: findings from the CRUSADE initiative. Am Heart J. 2010;159:757763.
  • 13
    Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics–2011 update: a report from the American Heart Association. Circulation. 2011;123:e18e209.
  • 14
    Hodgson J. Remodeling MMPIs. Biotechnology (N Y). 1995;13:554557.
  • 15
    Bachmann LH, Stephens J, Richey CM, Hook EW 3rd. Measured versus self-reported compliance with doxycycline therapy for chlamydia-associated syndromes: high therapeutic success rates despite poor compliance. Sex Transm Dis. 1999;26:272278.
  • 16
    Renkiewicz R, Qiu L, Lesch C, et al. Broad-spectrum matrix metalloproteinase inhibitor marimastat-induced musculoskeletal side effects in rats. Arthritis Rheum. 2003;48:17421749.
  • 17
    Skiles JW, Gonnella NC, Jeng AY. The design, structure, and therapeutic application of matrix metalloproteinase inhibitors. Curr Med Chem. 2001;8:425474.
  • 18
    Whittaker M, Floyd CD, Brown P, Gearing AJ. Design and therapeutic application of matrix metalloproteinase inhibitors. (Chem. Rev. 1999, 99, 2735-2776. Published on the web september 8, 1999). Chem Rev. 2001;101:22052206.
  • 19
    Peterson JT. Matrix metalloproteinase inhibitor development and the remodeling of drug discovery. Heart Fail Rev. 2004;9:6379.
  • 20
    Barilla ML, Carsons SE. Fibronectin fragments and their role in inflammatory arthritis. Semin Arthritis Rheum. 2000;29:252265.
  • 21
    Homandberg GA. Potential regulation of cartilage metabolism in osteoarthritis by fibronectin fragments. Front Biosci. 1999;4:D713D730.
  • 22
    Poole AR, Nelson F, Dahlberg L, et al. Proteolysis of the collagen fibril in osteoarthritis. Biochem Soc Symp. 2003:115123.
  • 23
    Weathington NM, van Houwelingen AH, Noerager BD, et al. A novel peptide CXCR ligand derived from extracellular matrix degradation during airway inflammation. Nat Med. 2006;12:317323.
  • 24
    Mihardja SS, Yu J, Lee RJ. Extracellular matrix-derived peptides and myocardial repair. Cell Adh Migr. 2011;5:111113.
  • 25
    Mihardja SS, Gao D, Sievers RE, et al. Targeted in vivo extracellular matrix formation promotes neovascularization in a rodent model of myocardial infarction. PLoS ONE. 2010;5:e10384.
  • 26
    Yu J, Christman KL, Chin E, et al. Restoration of left ventricular geometry and improvement of left ventricular function in a rodent model of chronic ischemic cardiomyopathy. J Thorac Cardiovasc Surg. 2009;137:180187.
  • 27
    Christman KL, Fok HH, Sievers RE, et al. Fibrin glue alone and skeletal myoblasts in a fibrin scaffold preserve cardiac function after myocardial infarction. Tissue Eng. 2004;10:403409.
  • 28
    Cleutjens JP, Verluyten MJ, Smiths JF, Daemen MJ. Collagen remodeling after myocardial infarction in the rat heart. Am J Pathol. 1995;147:325338.
  • 29
    Lopez B, Gonzalez A, Hermida N, et al. Role of lysyl oxidase in myocardial fibrosis: from basic science to clinical aspects. Am J Physiol Heart Circ Physiol. 2010;299:H1H9.
  • 30
    Casscells W, Kimura H, Sanchez JA, et al. Immunohistochemical study of fibronectin in experimental myocardial infarction. Am J Pathol. 1990;137:801810.
  • 31
    McCurdy SM, Dai Q, Zhang J, et al. SPARC mediates early extracellular matrix remodeling following myocardial infarction. Am J Physiol Heart Circ Physiol. 2011;301:H497H505.
  • 32
    Shimazaki M, Nakamura K, Kii I, et al. Periostin is essential for cardiac healing after acute myocardial infarction. J Exp Med. 2008;205:295303.
  • 33
    Dobaczewski M, Bujak M, Zymek P, et al. Extracellular matrix remodeling in canine and mouse myocardial infarcts. Cell Tissue Res. 2006;324:475488.
  • 34
    Tamaoki M, Imanaka-Yoshida K, Yokoyama K, et al. Tenascin-C regulates recruitment of myofibroblasts during tissue repair after myocardial injury. Am J Pathol. 2005;167:7180.
  • 35
    Frangogiannis NG, Ren G, Dewald O, et al. Critical role of endogenous thrombospondin-1 in preventing expansion of healing myocardial infarcts. Circulation. 2005;111:29352942.
  • 36
    Knowlton AA, Connelly CM, Romo GM, et al. Rapid expression of fibronectin in the rabbit heart after myocardial infarction with and without reperfusion. J Clin Investig. 1992;89:10601068.
  • 37
    Wiggers H, Klebe T, Heickendorff L, et al. Ischemia and reperfusion of the porcine myocardium: effect on collagen. J Mol Cell Cardiol. 1997;29:289299.
  • 38
    Cannon RO 3rd, Butany JW, McManus BM, et al. Early degradation of collagen after acute myocardial infarction in the rat. Am J Cardiol. 1983;52:390395.
  • 39
    Imanaka-Yoshida K, Hiroe M, Nishikawa T, et al. Tenascin-C modulates adhesion of cardiomyocytes to extracellular matrix during tissue remodeling after myocardial infarction. Lab Invest. 2001;81:10151024.
  • 40
    Ip JE, Wu Y, Huang J, et al. Mesenchymal stem cells use integrin beta1 not CXC chemokine receptor 4 for myocardial migration and engraftment. Mol Biol Cell. 2007;18:28732882.
  • 41
    Trueblood NA, Xie Z, Communal C, et al. Exaggerated left ventricular dilation and reduced collagen deposition after myocardial infarction in mice lacking osteopontin. Circ Res. 2001;88:10801087.
  • 42
    Oka T, Xu J, Kaiser RA, et al. Genetic manipulation of periostin expression reveals a role in cardiac hypertrophy and ventricular remodeling. Circ Res. 2007;101:313321.
  • 43
    Komatsubara I, Murakami T, Kusachi S, et al. Spatially and temporally different expression of osteonectin and osteopontin in the infarct zone of experimentally induced myocardial infarction in rats. Cardiovasc Pathol. 2003;12:186194.
  • 44
    Sezaki S, Hirohata S, Iwabu A, et al. Thrombospondin-1 is induced in rat myocardial infarction and its induction is accelerated by ischemia/reperfusion. Exp Biol Med (Maywood). 2005;230:621630.
  • 45
    Lal A, Veinot JP, Ganten D, Leenen FH. Prevention of cardiac remodeling after myocardial infarction in transgenic rats deficient in brain angiotensinogen. J Mol Cell Cardiol. 2005;39:521529.
  • 46
    Morishita N, Kusachi S, Yamasaki S, et al. Sequential changes in laminin and type IV collagen in the infarct zone–immunohistochemical study in rat myocardial infarction. Jpn Circ J. 1996;60:108114.
  • 47
    Chan CY, Chen YS, Lee HH, et al. Erythropoietin protects post-ischemic hearts by preventing extracellular matrix degradation: role of Jak2-ERK pathway. Life Sci.2007;81:717723.